Antares takes cost-cutting measures:
This article was originally published in Clinica
Antares Pharma has decided to close its manufacturing and assembly facilities in Minneapolis, Minnesota, and outsource these activities. The company, which is developing needle-free injectors and transdermal gel products, says it wants to focus on design and engineering rather than investing its resources in expanding its production capabilities. The company restructured its debt financing earlier this month. Its partner, Ferring Pharmaceuticals, recently launched its Vision reusable device, and Lilly is examining the possibility of using its needle-free technology with several of its pharmaceuticals.
You may also be interested in...
The Personal Care Products Council is engaging on state legislation for extended producer responsibility programs, which impose the cost of recycling plastic materials on manufacturers. Emerging bills to prohibit use of the ‘chasing arrows’ recycling symbol on consumer packaging also have the trade group’s attention.
A workshop broadcast from White Oak was a shift from the fully virtual meetings held since the height of the COVID-19 pandemic and may be a step toward once again staging public events there.
With two weeks to go before hearing on whether the preterm birth prevention drug can stay on the market or be withdrawn, the lack of clarity on who will make the ultimate decision may stem from the lengthy duration of the dispute and multiple transitions within FDA’s senior leadership.